Oxurion NV — Share Issue/Capital Change 2012

May 24, 2012

Regulated information

ThromboGenics increases share capital through warrant exercises

Leuven, Belgium – May 23, 2012 - ThromboGenics NV (NYSE Euronext: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announced today a capital increase arising from employee warrant exercises.

Since its inception in 2006, ThromboGenics has used warrant plans to incentivize personnel and management and have them share in the success of the company. Following warrant exercises during the exercise period in May 2012, ThromboGenics issued 121,917 new ordinary shares on 21 May 2012 for a total capital increase (including issuance premium) of €1,383,132.05.

To date, ThromboGenics total share capital amounts to €161,140,106.37; the total number of securities conferring voting rights is 35,813,349 which is also the total number of voting rights (the "denominator"). All voting rights are of the same category.

- End -

For further information please contact:

ThromboGenics

Chris Buyse, CFO Tel: + 32 16 75 13 10 chris.buyse@thrombogenics.com

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company's lead product, ocriplasmin, has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic Vitreomacular Adhesion (VMA). The MAA for ocriplasmin has been accepted for review in Europe and a BLA was re-submitted in the U.S. in April 2012. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.

In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments, plus an attractive level of royalties on Alcon's net sales of ocriplasmin. ThromboGenics and Alcon intend to share the costs equally of developing ocriplasmin for a number of new vitreoretinal indications.

ThromboGenics is also developing two novel antibody therapeutics in collaboration with BioInvent International. These are TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF), in Phase Ib/II for cancer, which has been partnered with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.